138 related articles for article (PubMed ID: 10688628)
1. New insights on effect of kidney insufficiency on disposition of angiotensin-converting enzyme inhibitors: case of enalapril and benazepril in dogs.
Toutain PL; Lefebvre HP; Laroute V
J Pharmacol Exp Ther; 2000 Mar; 292(3):1094-103. PubMed ID: 10688628
[TBL] [Abstract][Full Text] [Related]
2. Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites.
Lefebvre HP; Laroute V; Concordet D; Toutain PL
J Vet Intern Med; 1999; 13(1):21-7. PubMed ID: 10052059
[TBL] [Abstract][Full Text] [Related]
3. Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach.
Toutain PL; Lefebvre HP; King JN
J Pharmacol Exp Ther; 2000 Mar; 292(3):1087-93. PubMed ID: 10688627
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacokinetic/pharmacodynamic relationships for angiotensin-converting enzyme inhibitors.
Toutain PL; Lefèbvre HP
J Vet Pharmacol Ther; 2004 Dec; 27(6):515-25. PubMed ID: 15601445
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs.
King JN; Mauron C; Kaiser G
Am J Vet Res; 1995 Dec; 56(12):1620-8. PubMed ID: 8599524
[TBL] [Abstract][Full Text] [Related]
6. High serum enalaprilat in chronic renal failure.
Elung-Jensen T; Heisterberg J; Kamper AL; Sonne J; Strandgaard S; Larsen NE
J Renin Angiotensin Aldosterone Syst; 2001 Dec; 2(4):240-5. PubMed ID: 11881130
[TBL] [Abstract][Full Text] [Related]
7. Renal actions of the new angiotensin-converting enzyme inhibitor benazepril hydrochloride.
Levens NR
Arch Int Pharmacodyn Ther; 1988; 296():131-43. PubMed ID: 2853611
[TBL] [Abstract][Full Text] [Related]
8. Clearance of imidapril, an Angiotensin-converting enzyme inhibitor, during hemodialysis in hypertensive renal failure patients: comparison with quinapril and enalapril.
Tsuruoka S; Kitoh Y; Kawaguchi A; Sugimoto K; Hayasaka T; Saito T; Fujimura A
J Clin Pharmacol; 2007 Feb; 47(2):259-63. PubMed ID: 17244777
[TBL] [Abstract][Full Text] [Related]
9. Plasma concentrations of an angiotensin-converting enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, after repeated administrations of benazepril in dogs with experimental kidney impairment.
Kitagawa H; Eguchi T; Kitoh K; Ohba Y; Kondo M; Nakano M; Sasaki Y
J Vet Med Sci; 2000 Feb; 62(2):179-85. PubMed ID: 10720188
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats.
King JN; Maurer M; Toutain PL
J Vet Pharmacol Ther; 2003 Jun; 26(3):213-24. PubMed ID: 12755906
[TBL] [Abstract][Full Text] [Related]
11. Effect of renal insufficiency on the pharmacokinetics and pharmacodynamics of benazepril in cats.
King JN; Strehlau G; Wernsing J; Brown SA
J Vet Pharmacol Ther; 2002 Oct; 25(5):371-8. PubMed ID: 12423228
[TBL] [Abstract][Full Text] [Related]
12. Effects of angiotensin converting enzyme inhibitor on renal function in patients of membranoproliferative glomerulonephritis with mild to moderate renal insufficiency.
Giri S; Mahajan SK; Sen R; Sharma A
J Assoc Physicians India; 2002 Oct; 50():1245-9. PubMed ID: 12568207
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetics of benazepril relative to other ACE inhibitors.
Gengo FM; Brady E
Clin Cardiol; 1991 Aug; 14(8 Suppl 4):IV44-50; discussion IV51-5. PubMed ID: 1893642
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of the angiotensin-converting-enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, in dog.
King JN; Maurer M; Morrison CA; Mauron C; Kaiser G
Xenobiotica; 1997 Aug; 27(8):819-29. PubMed ID: 9293618
[TBL] [Abstract][Full Text] [Related]
15. Differential renal handling of angiotensin-converting enzyme inhibitors enalaprilat and lisinopril in rats.
Lin JH; Chen IW; Ulm EH; Duggan DE
Drug Metab Dispos; 1988; 16(3):392-6. PubMed ID: 2900730
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics of the newer ACE inhibitors. A review.
Kelly JG; O'Malley K
Clin Pharmacokinet; 1990 Sep; 19(3):177-96. PubMed ID: 2203579
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of a nitric oxide-releasing derivative of enalapril in male beagles.
Okuyama CE; Mendes GD; Faro R; Rezende VM; Lagos RM; Astigarraga RE; Antunes E; De Nucci G
Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):290-5. PubMed ID: 17324140
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics of angiotensin converting enzyme inhibitors in patients with renal impairment.
Begg EJ; Bailey RR; Lynn KL; Robson RA; Frank GJ; Olson SC
J Hypertens Suppl; 1989 Sep; 7(5):S29-32. PubMed ID: 2681603
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of spirapril and spiraprilat in patients with chronic renal failure.
Stein G; Sierakowski B; Grass P; Haufe CC; Jansa U; Weidinger G
Blood Press Suppl; 1994; 2():47-53. PubMed ID: 8061846
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin-converting enzyme inhibitors in the therapy of renal diseases.
Lefebvre HP; Toutain PL
J Vet Pharmacol Ther; 2004 Oct; 27(5):265-81. PubMed ID: 15500563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
